WealthTrust Axiom’s Trevi Therapeutics TRVI Stock Holding History

WealthTrust Axiom’s Portfolio TRVI Stock Details TRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.15M	Hold	61,500	–	–	0.26%	85
2026 Q1	$734K	Hold	61,500	–	–	0.18%	108
2025 Q4	$770K	Hold	61,500	–	–	0.2%	102
2025 Q3	$563K	Hold	61,500	–	–	0.15%	134
2025 Q2	$336K	Sell	61,500 -2,000	-3%	-$12.4K	0.1%	172
2025 Q1	$399K	Sell	63,500 -2,000	-3%	-$9.54K	0.12%	155
2024 Q4	$270K	Buy	65,500 +2,000	+3%	+$6.4K	0.08%	193
2024 Q3	$212K	Hold	63,500	–	–	0.06%	230
2024 Q2	$189K	Hold	63,500	–	–	0.06%	226
2024 Q1	$219K	Hold	63,500	–	–	0.07%	219
2023 Q4	$85.1K	Sell	63,500 -30,000	-32%	-$45.4K	0.03%	236
2023 Q3	$204K	Hold	93,500	–	–	0.07%	208
2023 Q2	$223K	Hold	93,500	–	–	0.07%	211
2023 Q1	$173K	Hold	93,500	–	–	0.06%	219
2022 Q4	$180K	Hold	93,500	–	–	0.06%	212
2022 Q3	$143K	Hold	93,500	–	–	0.05%	216
2022 Q2	$262K	Sell	93,500 -5,000	-5%	-$12.3K	0.09%	179
2022 Q1	$216K	Buy	98,500 +70,000	+246%	+$72.5K	0.07%	217
2021 Q4	$22K	Sell	28,500 -8,000	-22%	-$8.4K	0.01%	259
2021 Q3	$51K	Sell	36,500 -3,000	-8%	-$5.31K	0.02%	246
2021 Q2	$88K	Buy	39,500 +1,000	+3%	+$2.25K	0.03%	249
2021 Q1	$104K	Buy	38,500 +27,000	+235%	+$79.1K	0.04%	232
2020 Q4	$27K	Buy	+11,500	New	+$37.2K	0.01%	236

Other funds holding TRVI

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

WealthTrust Axiom's TRVI Position: Q2 2026 in Review

WealthTrust Axiom held its Trevi Therapeutics (TRVI) position steady in Q2 2026 at 61,500 shares worth $1.15M. The position accounts for 0.26% of the portfolio, ranked #85.

WealthTrust Axiom first reported a position in TRVI in Q4 2020 and has held it in 23 quarters since. 218 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

WealthTrust Axiom held 61,500 shares of Trevi Therapeutics worth $1.15M as of Q2 2026.
WealthTrust Axiom left its Trevi Therapeutics share count unchanged in Q2 2026.
Trevi Therapeutics made up 0.26% of WealthTrust Axiom's portfolio in Q2 2026, its #85 holding.
WealthTrust Axiom first reported a position in Trevi Therapeutics in Q4 2020 and has held it in 23 quarters since.
218 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on WealthTrust Axiom's 13F filing for Q2 2026, filed 11 Aug 2026.